Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

  • In development
  • GID-HST10062
  • Expected publication date: TBC

 

 
Following discussions with the company, the evaluation is due to start in late March 2026. Submissions are expected in early June 2026.